Robbert J Kok

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9542815/publications.pdf

Version: 2024-02-01

123 papers	6,502 citations	57758 44 h-index	69250 77 g-index
124 all docs	124 docs citations	124 times ranked	9515 citing authors

#	Article	IF	Citations
1	Post-loading of proangiogenic growth factors in PLGA microspheres. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 1-10.	4.3	12
2	In Vitro and In Vivo Studies on HPMA-Based Polymeric Micelles Loaded with Curcumin. Molecular Pharmaceutics, 2021, 18, 1247-1263.	4.6	29
3	Assessing the Effects of VEGF Releasing Microspheres on the Angiogenic and Foreign Body Response to a 3D Printed Silicone-Based Macroencapsulation Device. Pharmaceutics, 2021, 13, 2077.	4.5	7
4	Vascular Endothelial Growth Factorâ€“Releasing Microspheres Based on Poly(Îµ-Caprolactone-PEG-Îµ-Caprolactone)-b-Poly(L-Lactide) Multiblock Copolymers Incorporated in a Three-Dimensional Printed Poly(Dimethylsiloxane) Cell Macroencapsulation Device. Journal of Pharmaceutical Sciences, 2020, 109, 863-870.	3.3	15
5	Correlation between in vitro stability and pharmacokinetics of poly(Îµ-caprolactone)-based micelles loaded with a photosensitizer. Journal of Controlled Release, 2020, 328, 942-951.	9.9	12
6	Folate decorated polymeric micelles for targeted delivery of the kinase inhibitor dactolisib to cancer cells. International Journal of Pharmaceutics, 2020, 582, 119305.	5.2	21
7	Ï€-Ï€-Stacked Poly(Îµ-caprolactone)-b-poly(ethylene glycol) Micelles Loaded with a Photosensitizer for Photodynamic Therapy. Pharmaceutics, 2020, 12, 338.	4.5	6
8	Polymeric Micelles Employing Platinum(II) Linker for the Delivery of the Kinase Inhibitor Dactolisib. Particle and Particle Systems Characterization, 2019, 36, 1900236.	2.3	3
9	Sustained Release of Vascular Endothelial Growth Factor from Poly(Îµ-caprolactone-PEG-Îµ-caprolactone)-b-Poly(<scp>l</scp>-lactide) Multiblock Copolymer Microspheres. ACS Omega, 2019, 4, 11481-11492.	3.5	21
10	Connective Tissue Growth Factor Is Related to All-cause Mortality in Hemodialysis Patients and Is Lowered by On-line Hemodiafiltration: Results from the Convective Transport Study. Toxins, 2019, 11, 268.	3.4	3
11	Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro. Nanotechnology, 2019, 30, 264001.	2.6	14
12	Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery. Journal of Drug Targeting, 2019, 27, 681-689.	4.4	21
13	Colloidal formulation of mistletoe extracts in a pharmaceutical flow process for targeted cancer therapy. Phytomedicine, 2019, 61, 1.	5.3	1
14	Ultrasound-Sensitive Liposomes for Triggered Macromolecular Drug Delivery: Formulation and In Vitro Characterization. Frontiers in Pharmacology, 2019, 10, 1463.	3.5	30
15	Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys. Journal of Controlled Release, 2019, 293, 113-125.	9.9	19
16	Reversibly core-crosslinked PEG-P(HPMA) micelles: Platinum coordination chemistry for competitive-ligand-regulated drug delivery. Journal of Colloid and Interface Science, 2019, 535, 505-515.	9.4	23
17	Adsorption of phospholipids at oil/water interfaces during emulsification is controlled by stress relaxation and diffusion. Soft Matter, 2018, 14, 3730-3737.	2.7	12
18	Quantitative analysis of receptor-mediated uptake and pro-apoptotic activity of mistletoe lectin-1 by high content imaging. Scientific Reports, 2018, 8, 2768.	3.3	26

#	Article	IF	Citations
19	Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells. Pharmaceutical Research, 2018, 35, 85.	3.5	22
20	PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium. International Journal of Pharmaceutics, 2018, 548, 747-758.	5.2	40
21	Fabrication and characterization of gefitinib-releasing polyurethane foam as a coating for drug-eluting stent in the treatment of bronchotracheal cancer. International Journal of Pharmaceutics, 2018, 548, 803-811.	5.2	20
22	E-selectin targeted immunoliposomes for rapamycin delivery to activated endothelial cells. International Journal of Pharmaceutics, 2018, 548, 759-770.	5.2	31
23	Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information. Journal of Controlled Release, 2018, 270, 268-274.	9.9	36
24	Instability Mechanisms of Water-in-Oil Nanoemulsions with Phospholipids: Temporal and Morphological Structures. Langmuir, 2018, 34, 572-584.	3.5	29
25	Influence of cholesterol inclusion on the doxorubicin release characteristics of lysolipid-based thermosensitive liposomes. International Journal of Pharmaceutics, 2018, 548, 778-782.	5.2	30
26	Thermosensitive liposomes for triggered release of cytotoxic proteins. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 211-221.	4.3	37
27	Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2391-2398.	2.2	6
28	Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating. European Journal of Pharmaceutical Sciences, 2017, 103, 94-103.	4.0	11
29	Effect of Particle Size on Drug Loading and Release Kinetics of Gefitinib-Loaded PLGA Microspheres. Molecular Pharmaceutics, 2017, 14, 459-467.	4.6	159
30	PulmoStent: In Vitro to In Vivo Evaluation of a Tissue Engineered Endobronchial Stent. Annals of Biomedical Engineering, 2017, 45, 873-883.	2.5	13
31	Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment. International Journal of Nanomedicine, 2016, Volume 11, 5027-5040.	6.7	40
32	Selection and fabrication of a non-woven polycarbonate urethane cover for a tissue engineered airway stent. International Journal of Pharmaceutics, 2016, 514, 255-262.	5.2	8
33	Gene based therapies for kidney regeneration. European Journal of Pharmacology, 2016, 790, 99-108.	3.5	7
34	Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease: the SMART study. Growth Factors, 2016, 34, 149-158.	1.7	19
35	Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges. International Journal of Pharmaceutics, 2016, 499, 358-367.	5.2	207
36	Inhibition of Octreotide Acylation Inside PLGA Microspheres by Derivatization of the Amines of the Peptide with a Self-Immolative Protecting Group. Bioconjugate Chemistry, 2016, 27, 576-585.	3.6	14

#	Article	IF	Citations
37	Locoregional cancer therapy using polymer-based drug depots. Drug Discovery Today, 2016, 21, 640-647.	6.4	25
38	Ligand-targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status. Fundamental Biomedical Technologies, 2016, , 163-200.	0.2	16
39	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. Journal of Diabetes Research, 2015, 2015, 1-11.	2.3	18
40	Polymer-Free Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents. Bioconjugate Chemistry, 2015, 26, 1277-1288.	3.6	64
41	Diverse origins of the myofibroblastâ€"implications for kidney fibrosis. Nature Reviews Nephrology, 2015, 11, 233-244.	9.6	210
42	Sunitinib microspheres based on [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers for ocular drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 368-377.	4.3	36
43	Formulation and characterization of microspheres loaded with imatinib for sustained delivery. International Journal of Pharmaceutics, 2015, 482, 123-130.	5.2	48
44	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research, 2015, 21, 5100-5109.	7.0	49
45	Release and pharmacokinetics of near-infrared labeled albumin from monodisperse poly(d,l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcapsular renal injection. Acta Biomaterialia, 2015, 22, 141-154.	8.3	8
46	Biocompatibility of poly(d,l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection. International Journal of Pharmaceutics, 2015, 482, 99-109.	5.2	11
47	Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres. Biomaterials, 2015, 42, 151-160.	11.4	39
48	Targeting Rapamycin to Podocytes Using a Vascular Cell Adhesion Molecule-1 (VCAM-1)-Harnessed SAINT-Based Lipid Carrier System. PLoS ONE, 2015, 10, e0138870.	2.5	35
49	Epac-Rap Signaling Reduces Oxidative Stress in the Tubular Epithelium. Journal of the American Society of Nephrology: JASN, 2014, 25, 1474-1485.	6.1	31
50	Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles. Biomaterials, 2014, 35, 601-610.	11.4	72
51	Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: Comparison of the porcine and rat responses. Journal of Controlled Release, 2014, 195, 2-10.	9.9	79
52	Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-capped PCLA-PEG-PCLA thermogels. Biomaterials, 2014, 35, 7919-7928.	11.4	73
53	Computer Modeling Assisted Design of Monodisperse PLGA Microspheres with Controlled Porosity Affords Zero Order Release of an Encapsulated Macromolecule for 3ÂMonths. Pharmaceutical Research, 2014, 31, 2844-2856.	3.5	29
54	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. Molecular Pharmaceutics, 2013, 10, 3717-3727.	4.6	26

#	Article	IF	Citations
55	Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews, 2013, 65, 1284-1298.	13.7	338
56	Targeting tumors with nanobodies for cancer imaging and therapy. Journal of Controlled Release, 2013, 172, 607-617.	9.9	172
57	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. Journal of Controlled Release, 2013, 165, 110-118.	9.9	88
58	Nanomedicines as Cancer Therapeutics: Current Status. Current Cancer Drug Targets, 2013, 13, 362-378.	1.6	123
59	Kinase Inhibitor Conjugates. Current Pharmaceutical Design, 2012, 18, 2891-2900.	1.9	7
60	121 Tumor-targeted Nanobullets for Anti-cancer Combination Therapy. European Journal of Cancer, 2012, 48, 38.	2.8	0
61	Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opinion on Drug Delivery, 2012, 9, 1225-1243.	5.0	116
62	A micelle-shedding thermosensitive hydrogel as sustained release formulation. Journal of Controlled Release, 2012, 162, 582-590.	9.9	50
63	Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. European Journal of Pharmacology, 2012, 694, 111-119.	3.5	18
64	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. International Journal of Nanomedicine, 2012, 7, 417.	6.7	22
65	Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. European Journal of Pharmaceutical Sciences, 2012, 45, 399-407.	4.0	38
66	Effect of GFR on Plasma N-Terminal Connective Tissue Growth Factor (CTGF) Concentrations. American Journal of Kidney Diseases, 2012, 59, 619-627.	1.9	21
67	Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases. Journal of Controlled Release, 2012, 157, 461-468.	9.9	25
68	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. Journal of Controlled Release, 2012, 159, 281-289.	9.9	83
69	Dendrimerâ€Based Macromolecular Conjugate for the Kidneyâ€Directed Delivery of a Multitargeted Sunitinib Analogue. Macromolecular Bioscience, 2012, 12, 93-103.	4.1	17
70	Controlled Release of Octreotide and Assessment of Peptide Acylation from Poly(D,L-lactide-co-hydroxymethyl glycolide) Compared to PLGA Microspheres. Pharmaceutical Research, 2012, 29, 110-120.	3.5	58
71	Development of a Cell-Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate. Bioconjugate Chemistry, 2011, 22, 540-545.	3.6	18
72	Oxidative stress in obstructive nephropathy. International Journal of Experimental Pathology, 2011, 92, 202-210.	1.3	100

#	Article	IF	Citations
73	How to screen non-viral gene delivery systems in vitro?. Journal of Controlled Release, 2011, 154, 218-232.	9.9	105
74	The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy. Drug Discovery Today, 2011, 16, 219-228.	6.4	65
75	DNA Nuclear Targeting Sequences for Non-Viral Gene Delivery. Pharmaceutical Research, 2011, 28, 1707-1722.	3.5	49
76	Characterization of drug-lysozyme conjugates by sheathless capillary electrophoresisâ€“time-of-flight mass spectrometry. Analytica Chimica Acta, 2011, 698, 77-83.	5.4	34
77	Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers, 2011, 16, 289-301.	1.9	55
78	Targeted Delivery of Kinase Inhibitors: A Nanomedicine Approach for Improved Selectivity in Cancer. Current Signal Transduction Therapy, 2011, 6, 267-278.	0.5	1
79	Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cellsâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 1344-1357.	13.7	130
80	Targeting podocyte-associated diseasesâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 1325-1336.	13.7	89
81	Drug targeting to the kidneyâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 1323-1324.	13.7	3
82	Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology, 2010, 51, NA-NA.	7.3	96
83	Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. American Journal of Physiology - Renal Physiology, 2010, 298, F1457-F1464.	2.7	25
84	c-Jun NH₂-Terminal Kinase Is Crucially Involved in Renal Tubulo-Interstitial Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 896-905.	2.5	58
85	Cell-specific Delivery of a Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor to Proximal Tubular Cells for the Treatment of Renal Fibrosis. Pharmaceutical Research, 2008, 25, 2427-2439.	3.5	44
86	Targets in Fibrotic Disorders. Pharmaceutical Research, 2008, 25, 2413-2415.	3.5	0
87	RGD-avidinâ€“biotin pretargeting to Î±vÎ²3 integrin enhances the proapoptotic activity of TNFÎ± related apoptosis inducing ligand (TRAIL). Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 225-235.	4.9	10
88	Renal targeting of kinase inhibitors. International Journal of Pharmaceutics, 2008, 364, 249-257.	5.2	22
89	Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. Journal of Controlled Release, 2008, 132, 200-207.	9.9	21
90	Inhibition of Renal Rho Kinase Attenuates Ischemia/Reperfusion-Induced Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 2086-2097.	6.1	62

#	Article	IF	Citations
91	Novel Therapeutic Targets for the Treatment of Tubulointerstitial Fibrosis. Current Signal Transduction Therapy, 2008, 3, 97-111.	0.5	5
92	Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs. Current Molecular Pharmacology, 2008, 1, 1-12.	1.5	15
93	Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 856-865.	2.5	76
94	Improved Efficacy of Î±_vÎ²₃-Targeted Albumin Conjugates by Conjugation of a Novel Auristatin Derivative. Molecular Pharmaceutics, 2007, 4, 686-694.	4.6	42
95	Antivascular Therapies: Targets Beyond the Vessel Wall. ChemMedChem, 2007, 2, 433-435.	3.2	4
96	Glomerular and tubular induction of the transcription factor câ€Jun in human renal disease. Journal of Pathology, 2007, 213, 219-228.	4.5	88
97	Delivery of the p38 MAPkinase Inhibitor SB202190 to Angiogenic Endothelial Cells:â€‰ Development of Novel RGD-Equipped and PEGylated Drugâ^'Albumin Conjugates Using Platinum(II)-Based Drug Linker Technology. Bioconjugate Chemistry, 2006, 17, 1246-1255.	3.6	45
98	Evaluation of RGD-Targeted Albumin Carriers for Specific Delivery of Auristatin E to Tumor Blood Vessels. Bioconjugate Chemistry, 2006, 17, 1385-1394.	3.6	51
99	Covalently Linked Au Nanoparticles to a Viral Vector:â€‰ Potential for Combined Photothermal and Gene Cancer Therapy. Nano Letters, 2006, 6, 587-591.	9.1	250
100	Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. Journal of Controlled Release, 2006, 111, 193-203.	9.9	50
101	Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules. Journal of Controlled Release, 2006, 116, e57.	9.9	1
102	Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphateâ€“containing RGD peptide liposomes inhibits experimental arthritis. Arthritis and Rheumatism, 2006, 54, 1198-1208.	6.7	164
103	Rational Design of RGDâ€“Albumin Conjugates for Targeted Delivery of the VEGF-R Kinase Inhibitor PTK787 to Angiogenic Endothelium. ChemMedChem, 2006, 1, 1200-1203.	3.2	33
104	Intracellular Delivery of the p38 Mitogen-Activated Protein Kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in Renal Tubular Cells: A Novel Strategy to Treat Renal Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 8-19.	2.5	59
105	Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 826, 220-225.	2.3	7
106	RENAL-SELECTIVE DELIVERY AND ANGIOTENSIN-CONVERTING ENZYME INHIBITION BY SUBCUTANEOUSLY ADMINISTERED CAPTOPRIL-LYSOZYME. Drug Metabolism and Disposition, 2005, 33, 683-688.	3.3	18
107	Differential effects of NF-ÎºB and p38 MAPK inhibitors and combinations thereof on TNF-Î±- and IL-1Î²-induced proinflammatory status of endothelial cells in vitro. American Journal of Physiology - Cell Physiology, 2005, 289, C1229-C1239.	4.6	135
108	RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resistance Updates, 2005, 8, 381-402.	14.4	412

#	Article	IF	Citations
109	Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 197-202.	1.7	11
110	A nonviral carrier for targeted gene delivery to tumor cells. Cancer Gene Therapy, 2004, 11, 156-164.	4.6	22
111	RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward ?v?3-expressing endothelial cells. International Journal of Cancer, 2004, 112, 279-285.	5.1	16
112	A Novel Strategy to Modify Adenovirus Tropism and Enhance Transgene Delivery to Activated Vascular Endothelial CellsIn VitroandIn Vivo. Human Gene Therapy, 2004, 15, 433-443.	2.7	124
113	In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharmaceutical Research, 2003, 20, 64-72.	3.5	65
114	Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasoneâ€“anti-E-selectin immunoconjugate. Biochemical Pharmacology, 2003, 65, 1729-1739.	4.4	24
115	Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. Journal of Controlled Release, 2003, 91, 115-122.	9.9	298
116	Selective Intracellular Delivery of Dexamethasone into Activated Endothelial Cells Using an E-Selectin-Directed Immunoconjugate. Journal of Immunology, 2002, 168, 883-889.	0.8	85
117	Preparation and Functional Evaluation of RGD-Modified Proteins as Î±vÎ²3Integrin Directed Therapeutics. Bioconjugate Chemistry, 2002, 13, 128-135.	3.6	134
118	LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATURE. Journal of Liposome Research, 2002, 12, 129-135.	3.3	17
119	Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. Journal of Controlled Release, 2002, 83, 241-251.	9.9	57
120	Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study. International Journal of Cancer, 2002, 102, 469-475.	5.1	66
121	Cellular handling of a dexamethasone-anti-E-selectin immunoconjugate by activated endothelial cells: comparison with free dexamethasone. Pharmaceutical Research, 2002, 19, 1730-1735.	3.5	22
122	Drug Delivery to the Kidneys and the Bladder with the Low Molecular Weight Protein Lysozyme. Renal Failure, 1998, 20, 211-217.	2.1	21
123	Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. Biomedical Applications, 1997, 693, 181-189.	1.7	49